It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
There is a growing need for surrogate biomarkers for Parkinson’s disease (PD). Structural analysis using magnetic resonance imaging with T1-weighted sequences has the potential to quantify histopathological changes. Degeneration is typically measured by the volume and shape of morphological changes. However, these changes appear late in the disease, preventing their use as surrogate markers. We investigated texture changes in 108 individuals, divided into three groups, matched in terms of sex and age: (1) healthy controls (n = 32); (2) patients with early-stage PD (n = 39); and (3) patients with late-stage PD and severe L-dopa-related complications (n = 37). All patients were assessed in off-treatment conditions. Statistical analysis of first- and second-order texture features was conducted in the substantia nigra, striatum, thalamus and sub-thalamic nucleus. Regions of interest volumetry and voxel-based morphometry were performed for comparison. Significantly different texture features were observed between the three populations, with some showing a gradual linear progression between the groups. The volumetric changes in the two PD patient groups were not significantly different. Texture features were significantly associated with clinical scores for motor handicap. These results suggest that texture features, measured in the nigrostriatal pathway at PD diagnosis, may be useful in predicting clinical progression of motor handicap.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Université de Lille, INSERM, U1172, CHU-Lille, Lille Neuroscience Cognition Research Centre, Lille, France (GRID:grid.503422.2) (ISNI:0000 0001 2242 6780)
2 Université de Lille, INSERM, U1172, CHU-Lille, Lille Neuroscience Cognition Research Centre, Lille, France (GRID:grid.503422.2) (ISNI:0000 0001 2242 6780); CHU Lille, Licend, Neurology and Movement Disorders Department, Lille, France (GRID:grid.410463.4) (ISNI:0000 0004 0471 8845)
3 CHU Lille, Licend, Neurology and Movement Disorders Department, Lille, France (GRID:grid.410463.4) (ISNI:0000 0004 0471 8845)
4 CATI, Institut du Cerveau et de le Moelle Epinière, INSERM, U1127, CNRS, UMR7225, Sorbonne, Université, Paris, France (GRID:grid.4444.0) (ISNI:0000 0001 2112 9282)
5 Université de Lille, INSERM, U1172, CHU-Lille, Lille Neuroscience Cognition Research Centre, Lille, France (GRID:grid.503422.2) (ISNI:0000 0001 2242 6780); CHU Lille, Licend, Department of Neuroradiology, Lille, France (GRID:grid.410463.4) (ISNI:0000 0004 0471 8845)